Start of partnership with major companies! Yufu BIO Medical, which challenges technological innovation in diagnostic medicine and industrialization of regenerative medicine through nanobiology, begins its second round of funding through e-cloud on September 7th. *E-Cloud Co., Ltd.*
Press release: August 27, 2024
**
Start of partnership with major companies! Yufu BIO Medical, which challenges technological innovation in diagnostic medicine and industrialization of regenerative medicine through nanobiology, begins its second round of funding through e-cloud on September 7th. *~Bio venture from Okinawa takes on equity investment crowdfunding~* E-Cloud Co., Ltd. (Chuo-ku, Tokyo, Representative Director: Naohiko Hatae, hereinafter referred to as “E-Cloud”), which provides stock investment crowdfunding services, has begun pre-disclosure for its 39th project, “Yufu BIO Medical.” . We will begin accepting investment applications from 10:00 on Saturday, September 7, 2024. (Details: https://ecrowd.co.jp/projects/39)
Summary of recruitment for project No. 39
Company name: Yufu BIO Medical Co., Ltd.
Business overview: Development and raw material manufacturing of in vitro test reagents, contract manufacturing, development and manufacturing support related to regenerative medicine, etc. Scheduled recruitment period: Start: Saturday, September 7, 2024 – End: Wednesday, September 25, 2024
Target recruitment amount: 10 million yen (upper limit recruitment amount: 60 million yen)
* Preventive medical care needs are increasing in a super-aging society; contributing to solving medical issues through quick and low-cost testing medical care*
Against the backdrop of rising medical costs associated with an aging population, the significance of “preventive medical care” is attracting more attention than ever. Indispensable for this preventive medical care is the process of in vitro testing, which performs health examinations and identifies diseases. In vitro testing is an area that is attracting attention, including testing for influenza and the new coronavirus, and the market is rapidly expanding.
Yufu BIO Medical’s main business is the research and development of rapid, low-cost, and highly sensitive in vitro test drugs that utilize unique technology in the nanobiology field that controls the surface of nanoparticles. Currently, there are methods such as the “ELISA method” and “latex agglutination method” for in vitro testing, but the product developed by Yufu BIO Medical reduces the test time, which was an issue with the ELISA method, to one-fourth. In-house experiments have shown that the test sensitivity, which had been an issue with latex agglutination methods, has been improved by up to five times.
Yufu BIO Medical aims to create a new standard in in vitro testing by collaborating with major global medical manufacturers and promoting business related to in vitro test drug development.
* Promoting local production for local consumption and export of regenerative medical services outside the prefecture at one of the largest cell culture processing facilities in the Kyushu and Okinawa regions *
In addition, we utilize one of the largest cell culture processing facilities (CPC) in the Kyushu and Okinawa regions to provide contract manufacturing and development and manufacturing support for
regenerative medicine. Regarding Japan’s first initiative to develop a supply chain platform for cell medicine (*) in collaboration with the Hitachi Group (Hitachi, Ltd./Hitachi Global Life Solutions), May 2023 joint release
is being announced.
*Cell medicine: Specified cell products provided based on the Regenerative Medicine Safety Act
Okinawa Prefecture positions bio-related industries as important industries. Yufu BIO Medical has been selected for the bio-related industry commercialization promotion project in 2020 and 2020, and will promote the industrialization of regenerative medicine while also utilizing government measures.
As mentioned above, Yufu BIO Medical is steadily making preparations to make its business leap forward. In order to further accelerate research and development and expand empathy for our vision and mission, we plan to begin raising funds from individual investors through the stock investment crowdfunding service “E-Cloud.”
* Three noteworthy points of Yufu BIO Medical Co., Ltd. *
・Develop rapid, low-cost, and highly sensitive test drugs using proprietary technology, aiming to reduce burden on patients and medical costs.
・Using one of the largest cell culture processing facilities in the Kyushu and Okinawa regions, we are expanding contract manufacturing, development and manufacturing support businesses related to
regenerative medicine both within and outside the prefecture. ・Started multiple new industry-industry collaborations to expand business. Progress and initiatives were evaluated and four new manufacturing-related administrative projects were selected. For more information, please see the eCloud recruitment page. Click here for the recruitment page * “Yufu BIO Medical” answers investors’ questions*
We will be accepting questions about Yufu BIO Medical from investors until 23:59 on Sunday, September 1, 2024.
We will be posting answers to questions from investors on the recruitment page (by Wednesday, September 4, 2024).
https://ecrowd.co.jp/projects/39).
If you have any questions about our business, strategy, financing, etc., please take this opportunity to ask them.
*Please note that we may not be able to answer depending on the content of your question.
*What is “stock investment crowdfunding” that allows you to become a shareholder of Yufu BIO Medical from around 100,000 yen*
“Equity investment crowdfunding” is a mechanism that allows small amounts of funds to be raised from many people over the Internet by issuing unlisted stocks, and is a means of raising funds that became possible with the revision of the Financial Instruments and Exchange Act in 2015. is.
Until now, opportunities for individuals to invest in unlisted startups have been extremely limited, but by utilizing “equity investment crowdfunding,” the hurdles to investing in startups have been reduced.
Startups have been attracting renewed attention in recent years as a key driver of Japan’s economic growth and problem solving. On the other hand, the bottleneck for startups is financing, and the government is considering expanding the system for “equity investment crowdfunding” as a way to strengthen the supply of funds to startups.
Through “equity investment crowdfunding,” E-Cloud aims to create a prosperous society where everyone can envision their ideal future and take on challenges.
*This press release is a document to publicly announce the decision on ECloud’s No. 39 project, and is not prepared for the purpose of soliciting investment.
◆Overview of Yufu BIO Medical Co., Ltd.
Trade name: Yufu BIO Medical Co., Ltd.
Head office location: 105 Okinawa Health Biotechnology Research and Development Center, 12-75 Susuzaki, Uruma City, Okinawa 904-2234 Representative Directors: Mathematics Nakahama, Masakaze Tani Service site: https://yukaze-biomedical.co.jp/
◆Overview of E-Cloud Co., Ltd.
Trade name: E-Cloud Co., Ltd.
Financial Instruments Business Operator Kanto Local Finance Bureau (Kinsho) No. 3181
Member association: Japan Securities Dealers Association
Head office location: 3rd floor, Tokyo Tatemono Yaesu Sakuradori Building, 1-5-20 Yaesu, Chuo-ku, Tokyo 103-0028
Representative Director: Naohiko Hatae
Service site: https://ecrowd.co.jp/
Corporate site: https://corp.ecrowd.co.jp/